|

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

RECRUITINGSponsored by Leiden University Medical Center
Actively Recruiting
SponsorLeiden University Medical Center
Started2023-01-01
Est. completion2027-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →

NCT06932081

Summary

This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Congenital heart defect.
* Age ≥ 18 years.
* Initiated on treatment with an SGLT2i.

Exclusion Criteria:

\- No consent for data collection.

Conditions9

Adult Congenital Heart DiseaseCongenital Heart DiseaseCongenitally Corrected Transposition of the Great ArteriesFontanHeart DiseaseSingle-ventricleSystemic Right VentricleTetralogy of Fallot (TOF)Transposition of the Great Arteries

Interventions1

SGLT2 inhibitors

Locations3 sites

Maryland

1 site
Johns Hopkins University
Baltimore, Maryland, 21205
Ari M. Cedars, MD PhD

Michigan

1 site
Helen DeVos Children's Hospital
Grand Rapids, Michigan, 49503
Gruschen R. Veldtman, MBChB FRCP

New York

1 site
Mount Sinai Fuster Heart Hospital
New York, New York, 10029
Ali Zaidi, MD

Find trials near these locations

Heart Disease trials in BaltimoreHeart Disease trials in New YorkAll trials in MarylandAll trials in New York

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.